Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. (Q38790312)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Lara Fontani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Stefano Gatti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Daniela Cantarella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Massimo Natale

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Mara Morello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Antonio Ponzetto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

James Cimino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

publication date

26 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

Journal of Molecular and Cellular Cardiology

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

84-97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

Heart disease and stroke statistics--2012 update: a report from the American Heart Association

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Genetic dissection of cardiac growth control pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hypertrophic cardiomyopathy: from genetics to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Signaling to cardiac hypertrophy: insights from human and mouse RASopathies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

The cardiofaciocutaneous syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Noonan syndrome and clinically related disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

MET signalling: principles and functions in development, organ regeneration and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

From Tpr-Met to Met, tumorigenesis and tubes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

A potential cardioprotective role of hepatocyte growth factor in myocardial infarction in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Involvement of receptor-type tyrosine kinase gene families in cardiac hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Aldosterone-Specific Activation of Cardiomyocyte Mineralocorticoid Receptor In Vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Gene transfection of hepatocyte growth factor attenuates the progression of cardiac remodeling in the hypertrophied heart.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Activated Met signalling in the developing mouse heart leads to cardiac disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Increased circulating hepatocyte growth factor in the early stage of acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

A multi-biomarker risk score improves prediction of long-term mortality in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Novel therapy for myocardial infarction: can HGF/Met be beneficial?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hepatocyte growth factor protects cardiac myocytes against oxidative stress-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hepatocyte growth factor/Met gene transfer in cardiac stem cells--potential for cardiac repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hepatocyte growth factor regulates the TGF-β1-induced proliferation, differentiation and secretory function of cardiac fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Invasive growth: a MET-driven genetic programme for cancer and stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Effect of hepatocyte growth factor and angiotensin II on rat cardiomyocyte hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Global gene expression profiling in the failing myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Conditional activation of MET in differentiated skeletal muscle induces atrophy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Gene expression profiling of HGF/Met activation in neonatal mouse heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Expander: from expression microarrays to networks and functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Functional analysis beyond enrichment: non-redundant reciprocal linkage of genes and biological terms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

DAVID: Database for Annotation, Visualization, and Integrated Discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

oPOSSUM: integrated tools for analysis of regulatory motif over-representation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

ERK1/2 activation in heart is controlled by melusin, focal adhesion kinase and the scaffold protein IQGAP1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Remodelling of gap junctions and connexin expression in diseased myocardium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hypertrophy of the heart: a new therapeutic target?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Regulation of cardiac hypertrophy by intracellular signalling pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

DUSP6 (MKP3) null mice show enhanced ERK1/2 phosphorylation at baseline and increased myocyte proliferation in the heart affecting disease susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Cardiac natriuretic peptides: from basic discovery to clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Oncostatin M stimulates tissue inhibitor of metalloproteinase-1 via a MEK-sensitive mechanism in human myofibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Glutathione suppresses TGF-beta-induced PAI-1 expression by inhibiting p38 and JNK MAPK and the binding of AP-1, SP-1, and Smad to the PAI-1 promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

TIMPs as multifacial proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Gene expression profile in the early stage of angiotensin II-induced cardiac remodeling: a time series microarray study in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

7 January 2021

PAI-1 in tissue fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Biomarkers of heart failure with normal ejection fraction: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Hepatocyte growth factor (HGF) as a potential index of severity of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

A novel vascular modulator, hepatocyte growth factor (HGF), as a potential index of the severity of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2016.02.017

10.1016/J.YJMCC.2016.02.017

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26924269%20AND%20SRC:MED&resulttype=core&format=json